TY - JOUR
T1 - Synthesis and Antiviral Activities of Neoechinulin B and Its Derivatives
AU - Nishiuchi, Kota
AU - Ohashi, Hirofumi
AU - Nishioka, Kazane
AU - Yamasaki, Masako
AU - Furuta, Masateru
AU - Mashiko, Takumi
AU - Tomoshige, Shusuke
AU - Ohgane, Kenji
AU - Kamisuki, Shinji
AU - Watashi, Koichi
AU - Kuramochi, Kouji
N1 - Funding Information:
Huh7.5.1 and VeroE6/TMPRSS2 cells were kindly provided by Dr. Francis Chisari at The Scripps Research Institute and Dr. Makoto Takeda at National Institute of Infectious Diseases, respectively. HCV JFH-1 strain and SARS-CoV-2 Wk-521 strain were kindly provided by Dr. Takaji Wakita at National Institute of Infectious Diseases and Dr. Shutoku Matsuyama at National Institute of Infectious Diseases. LXRE-driven luciferase plasmid was provided by Dr. Maiko Okada at Tokyo University of Technology. This work was supported by Program for Basic and Clinical Research on Hepatitis (JP20fk0210036) and Research Program on Emerging and Re-emerging Infectious Diseases (JP20fk0108411 and JP20fk0108511) from the Japan Agency for Medical Research and Development (AMED). This work was also supported by Smoking Research Foundation and Japan Society for the Promotion of Science KAKENHI (20H03499). In addition, this work was supported by an on-campus grant in TUS, funded by a donation from “Account for Donations to Develop Vaccine and Medicine to Treat COVID-19”, which was established by Sumitomo Mitsui Trust Bank, Limited. We acknowledge Ms. Asako Aoyagi for her invaluable assistance with the preparation of the manuscript.
Funding Information:
Huh7.5.1 and VeroE6/TMPRSS2 cells were kindly provided by Dr. Francis Chisari at The Scripps Research Institute and Dr. Makoto Takeda at National Institute of Infectious Diseases, respectively. HCV JFH-1 strain and SARS-CoV-2 Wk-521 strain were kindly provided by Dr. Takaji Wakita at National Institute of Infectious Diseases and Dr. Shutoku Matsuyama at National Institute of Infectious Diseases. LXRE-driven luciferase plasmid was provided by Dr. Maiko Okada at Tokyo University of Technology. This work was supported by Program for Basic and Clinical Research on Hepatitis (JP20fk0210036) and Research Program on Emerging and Re-emerging Infectious Diseases (JP20fk0108411 and JP20fk0108511) from the Japan Agency for Medical Research and Development (AMED). This work was also supported by Smoking Research Foundation and Japan Society for the Promotion of Science KAKENHI (20H03499). In addition, this work was supported by an on-campus grant in TUS, funded by a donation from ?Account for Donations to Develop Vaccine and Medicine to Treat COVID-19?, which was established by Sumitomo Mitsui Trust Bank, Limited. We acknowledge Ms. Asako Aoyagi for her invaluable assistance with the preparation of the manuscript.
Publisher Copyright:
© 2021 The Authors. Published by American Chemical Society and American Society of Pharmacognosy
PY - 2022/1/28
Y1 - 2022/1/28
N2 - We have previously reported that neoechinulin B (1a), a prenylated indole diketopiperazine alkaloid, shows antiviral activities against hepatitis C virus (HCV) via the inactivation of the liver X receptors (LXRs) and the resultant disruption of double-membrane vesicles. In this study, a two-step synthesis of the diketopiperazine scaffold of 1a was achieved by the base-induced coupling of 1,4-diacetyl-3-{[(tert-butyldimethylsilyl)oxy]methyl}piperazine-2,5-dione with aldehydes, followed by the treatment of the resultant coupling products with tetra-n-butylammonium fluoride. Compound 1a and its 16 derivatives 1b–q were prepared using this method. Furthermore, variecolorin H, a related alkaloid, was obtained by the acid treatment of 1a in MeOH. The antiviral evaluation of 1a and its derivatives revealed that 1a, 1c, 1d, 1h, 1j, 1l, and 1o exhibited both anti-HCV and anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) activities. The results of this study indicate that the exomethylene moiety on the diketopiperazine ring is important for the antiviral activities. The antiviral compounds can inhibit the production of HCV and SARS-CoV-2 by inactivating LXRs.
AB - We have previously reported that neoechinulin B (1a), a prenylated indole diketopiperazine alkaloid, shows antiviral activities against hepatitis C virus (HCV) via the inactivation of the liver X receptors (LXRs) and the resultant disruption of double-membrane vesicles. In this study, a two-step synthesis of the diketopiperazine scaffold of 1a was achieved by the base-induced coupling of 1,4-diacetyl-3-{[(tert-butyldimethylsilyl)oxy]methyl}piperazine-2,5-dione with aldehydes, followed by the treatment of the resultant coupling products with tetra-n-butylammonium fluoride. Compound 1a and its 16 derivatives 1b–q were prepared using this method. Furthermore, variecolorin H, a related alkaloid, was obtained by the acid treatment of 1a in MeOH. The antiviral evaluation of 1a and its derivatives revealed that 1a, 1c, 1d, 1h, 1j, 1l, and 1o exhibited both anti-HCV and anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) activities. The results of this study indicate that the exomethylene moiety on the diketopiperazine ring is important for the antiviral activities. The antiviral compounds can inhibit the production of HCV and SARS-CoV-2 by inactivating LXRs.
UR - http://www.scopus.com/inward/record.url?scp=85122800402&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122800402&partnerID=8YFLogxK
U2 - 10.1021/acs.jnatprod.1c01120
DO - 10.1021/acs.jnatprod.1c01120
M3 - Article
C2 - 34967639
AN - SCOPUS:85122800402
SN - 0163-3864
VL - 85
SP - 284
EP - 291
JO - Journal of Natural Products
JF - Journal of Natural Products
IS - 1
ER -